Back to search
FDAFDA · Food and drugs·Recall number D-0836-2020

Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 62037-725-01

Published February 19, 2020 · Recall initiated: January 27, 2020

Summary

FDA records drug Class II recall D-0836-2020, published February 19, 2020 and initiated January 27, 2020. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Lot: Lot #: 1332796 A, Exp 11/2020. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP deviations: Product bottle may be absent of desiccant.

What to do

Voluntary: Firm initiated · Letter

Get an email if METHYLPHENIDATE HYDROCHLORIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
METHYLPHENIDATE HYDROCHLORIDE
Manufacturer
Teva Pharmaceuticals USA
Distributor
USA Nationwide
Lot
Lot #: 1332796 A, Exp 11/2020
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 62037-725-01 recalled?

Yes. FDA published recall D-0836-2020 on February 19, 2020. Reported hazard: CGMP deviations: Product bottle may be absent of desiccant.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: METHYLPHENIDATE HYDROCHLORIDE.